Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk

The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Novo Nordisk in the GLP-1 medicine market. Foundayo is an oral medication offering a new option for weight management. Lilly plans to launch the pill soon, with further global approvals expected this year.